OncoMatch/Clinical Trials/NCT05183048
Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma
Is NCT05183048 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies [89Zr]Panitumumab Tracer for head and neck squamous cell carcinoma.
Treatment: [89Zr]Panitumumab Tracer — This pilot clinical study will investigate if Zirconium-89 (89Zr) panitumumab- Positron Emission Tomography/ Magnetic Resonance Imaging (PET/MRI) imaging can more accurately determine size and location of primary tumors compared to standard of care Fludeoxyglucose (18F-FDG) -PET/MRI in newly diagnosed patients with head and neck squamous cell carcinoma (HNSCC) who are undergoing surgical resection. This study is for imaging purposes only and is not a treatment study. The results of this study will not change the clinical treatment plan.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Prior therapy
Cannot have received: investigational drug
Received an investigational drug within 30 days prior to the first dose of [89Zr]panitumumab.
Cannot have received: surgical resection
Previous HNSCC resection.
Lab requirements
Blood counts
Hemoglobin ≥ 9 gm/dL; White blood cell count ≥ 3000/mm3; Platelet count ≥ 100,000/mm3
Kidney function
Serum creatinine ≤ 1.5 times upper reference range; Creatinine within normal institutional limits OR Creatinine clearance ≥60 mL/min/1.73 m2 for patients with creatinine levels; Severe renal disease or anuria [excluded]
Liver function
ALT (SGPT) 7-56 units/liter, AST (SGOT) 5-40 units/liter
Have acceptable hematologic status, coagulation status (11 to 13.5 seconds. international normalized ratio (INR) of 0.8 to 1.1), kidney function, and liver function including the following clinical results: Hemoglobin ≥ 9 gm/dL; White blood cell count ≥ 3000/mm3; Platelet count ≥ 100,000/mm3; Serum creatinine ≤ 1.5 times upper reference range; ALT (SGPT) 7-56 units/liter, AST (SGOT) 5-40 units/liter. Severe renal disease or anuria [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UAB · Birmingham, Alabama
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05183048 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior investigational drug, surgical resection disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages